KRAKacquisition earns $3.04M in Q3 on interest
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
KRAKacquisition Corp (KRAQ), a blank-check company seeking a business combination, reported net income of $3,044,603 for the three months ended September 30, 2026. The result included $3,202,863 of interest income, partly offset by $158,260 of general and administrative expenses. For the nine months, it recorded a $3,020,297 net loss, with $11,355,679 of general and administrative expenses partly offset by $8,335,382 of interest income. The company had not begun operations or generated operating revenue.
At September 30, KRAKacquisition held $352,953,916 in marketable securities in its trust account, had $756,757 in cash outside the trust and reported a $749,033 working-capital surplus. Management said the IPO left sufficient capital to sustain operations for one year from the financial statements’ issuance, alleviating previously disclosed substantial doubt. The company must complete a business combination by January 29, 2028 or face mandatory liquidation and dissolution. Deferred underwriting and advisory fees of $10,350,000 each are payable upon completion of a business combination.
Filing Explained
Public shareholders retain a deal-time trust-redemption option; founder shares convert at a combination, while warrant shares remain contingent on later exercise.
This unaudited quarterly report describes KRAKacquisition Corp as still pursuing a business combination and reports none completed as of
The filing records all 34,500,000 public shares as temporary equity at
The 8,625,000 Class B founder shares convert into Class A shares one-for-one at the combination, subject to an adjustment that can set the converted founder stake at approximately
Key Figures
Key Terms
temporary equity financial
Trust Account financial
over-allotment option financial
redemption value financial
working capital surplus financial
deferred underwriting discount financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were KRAQ’s net income and net loss in its September 2026 quarterly report?
When must KRAQ complete a business combination?
What was KRAQ’s Class A share redemption value?
AI-generated analysis. How Rhea-AI works. Not financial advice.
| QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
| | | |
| (State or other jurisdiction of Incorporation or organization) | (I.R.S. Employer Identification Number) |
| | 94025 | |
| (Address of principal executive offices) | (Zip Code) | |
| Registrant’s telephone number, including area code: | ( |
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| | | The | ||
| | | The | ||
| | | The |
| Large accelerated filer ☐ | Accelerated filer ☐ | |
| | Smaller reporting company | |
| Emerging growth company |
|
Page
|
|
|
PART I – Financial Information
|
|
|
Item 1: Financial Statements
|
F-2
|
|
Condensed Balance Sheets as of September 30, 2026 (Unaudited) and December 31, 2025
|
F-2
|
|
Condensed Statements of Operations for the Three and Nine Months Ended September 30, 2026 (Unaudited) and for the Period from July 28, 2025
(Inception) through September 30, 2025 (Unaudited)
|
F-3
|
|
Condensed Statements of Changes in Shareholders’ Deficit for the Three and Nine Months Ended September 30, 2026 (Unaudited) and for the Period from July
28, 2025 (Inception) through September 30, 2025 (Unaudited)
|
F-4
|
|
Condensed Statements of Cash Flows for the Nine Months Ended September 30, 2026 (Unaudited) and for the Period from July 28, 2025 (Inception) through September 30, 2025 (Unaudited)
|
F-5
|
|
Notes to Unaudited Condensed Financial Statements
|
F-6
|
|
Item 2: Management’s Discussion and Analysis of Financial Condition and Results of Operations
|
1
|
|
Item 3: Quantitative and Qualitative Disclosures about Market Risks
|
5
|
|
Item 4: Controls and Procedures
|
5
|
|
PART II – Other Information
|
5
|
|
Item 1: Legal Proceedings
|
5
|
|
Item 1A: Risk Factors
|
5
|
|
Item 2: Unregistered Sales of Equity Securities and Use of Proceeds
|
5
|
|
Item 3: Default Upon Senior Securities
|
5
|
|
Item 4: Mine Safety Disclosures
|
5
|
|
Item 5: Other Information
|
5
|
|
Item 6: Exhibits
|
6
|
|
Signatures
|
7
|
| Item 1. | Financial Statements |
| September 30, 2026 |
December 31, 2025 |
|||||||
| (Unaudited) |
||||||||
|
ASSETS
|
||||||||
|
Current assets:
|
||||||||
|
Cash and cash equivalents
|
$
|
|
$
|
|
||||
|
Prepaid insurance - current
|
|
|
||||||
|
Total current assets
|
|
|
||||||
|
Prepaid insurance - non-current
|
|
|
||||||
|
Marketable securities held in Trust Account
|
|
|
||||||
|
Deferred offering costs
|
|
|
||||||
|
TOTAL ASSETS
|
$
|
|
$
|
|
||||
|
LIABILITIES, CLASS A ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION AND SHAREHOLDERS’ DEFICIT
|
||||||||
|
Current liabilities:
|
||||||||
|
Accrued offering costs
|
$
|
|
$
|
|
||||
|
Accounts payable
|
|
|
||||||
|
Accrued expenses
|
|
|
||||||
|
Due to related party
|
|
|
||||||
|
Promissory note - related party
|
|
|
||||||
|
Total current liabilities
|
|
|
||||||
|
Deferred underwriting fee payable
|
|
|
||||||
|
Advisory fee payable
|
|
|
||||||
|
Total Liabilities
|
|
|
||||||
|
Commitments and Contingencies (Note 7)
|
||||||||
| Class A ordinary shares subject to possible redemption, |
|
|
||||||
|
Shareholders’ Deficit
|
||||||||
| Preference shares, $ |
|
|
||||||
| Class A ordinary shares, $ |
|
|
||||||
| Class B ordinary shares, $ |
|
|
||||||
|
Additional paid-in capital
|
|
|
||||||
|
Accumulated deficit
|
( |
)
|
( |
)
|
||||
|
Total Shareholders’ Deficit
|
( |
)
|
( |
)
|
||||
|
TOTAL LIABILITIES CLASS A ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION AND SHAREHOLDERS’ DEFICIT
|
$
|
|
$
|
|
||||
| (1) | |
| For the Three Months Ended September 30, 2026 |
For the Nine Months Ended September 30, 2026 |
For the Period from July 28, 2025 (inception) through September 30, 2025 |
||||||||||
|
Operating expenses:
|
||||||||||||
|
General and administrative expenses
|
$
|
|
$
|
|
$
|
|
||||||
|
Loss from operations
|
( |
)
|
( |
)
|
( |
)
|
||||||
|
Other income:
|
||||||||||||
|
Interest income on marketable securities held in trust account and cash equivalents held in operating account
|
|
|
|
|||||||||
|
Total other income
|
|
|
|
|||||||||
|
Net income (loss)
|
$
|
|
$
|
( |
)
|
$
|
( |
)
|
||||
|
Weighted average shares outstanding, Class A ordinary shares
|
|
|
|
|||||||||
|
Basic and diluted net income (loss) per Class A ordinary share
|
$
|
|
$
|
( |
)
|
$
|
|
|||||
|
Weighted average shares outstanding, Class B ordinary shares(1)
|
|
|
|
|||||||||
|
Basic and diluted net income (loss) per Class B ordinary share
|
$
|
|
$
|
( |
)
|
$
|
( |
)
|
||||
| (1) | |
| Class B Ordinary Shares |
Additional Paid- |
Accumulated |
Total Shareholders’ |
|||||||||||||||||
| Shares |
Amount |
in Capital |
Deficit |
Deficit |
||||||||||||||||
|
Balance at July 1, 2026
|
|
$
|
|
$
|
|
$
|
( |
)
|
$
|
( |
)
|
|||||||||
|
Accretion of Class A ordinary shares subject to possible redemption to redemption value
|
—
|
|
|
( |
)
|
( |
)
|
|||||||||||||
|
Net income
|
—
|
|
|
|
|
|||||||||||||||
|
Balance at September 30, 2026 (unaudited)
|
|
$
|
|
$
|
|
$
|
( |
)
|
$
|
( |
)
|
|||||||||
| Class B Ordinary Shares (1) |
Additional Paid- |
Accumulated |
Total Shareholders’ |
|||||||||||||||||
| Shares |
Amount |
in Capital |
Deficit |
Deficit |
||||||||||||||||
|
Balance at January 1, 2026
|
|
$
|
|
$
|
|
$
|
( |
)
|
$
|
( |
)
|
|||||||||
|
Proceeds from Private Warrants, less issuance costs
|
—
|
|
|
|
|
|||||||||||||||
|
Proceeds from sale of Public Warrants, less issuance costs
|
—
|
|
|
|
|
|||||||||||||||
|
Accretion of Class A ordinary shares subject to possible redemption to redemption value
|
—
|
|
( |
)
|
( |
)
|
( |
)
|
||||||||||||
|
Net loss
|
—
|
|
|
( |
)
|
( |
)
|
|||||||||||||
|
Balance at September 30, 2026 (unaudited)
|
|
$
|
|
$
|
|
$
|
( |
)
|
$
|
( |
)
|
|||||||||
| Class B Ordinary Shares (1) |
Additional Paid- |
Accumulated |
Total Shareholders’ |
|||||||||||||||||
| Shares |
Amount |
in Capital |
Deficit |
Deficit |
||||||||||||||||
|
Balance at July 28, 2025 (inception)
|
|
$
|
|
$
|
|
$
|
|
$
|
|
|||||||||||
|
Issuance of Class B ordinary shares to Sponsor
|
|
|
|
|
|
|||||||||||||||
|
Net loss
|
—
|
|
|
( |
)
|
( |
)
|
|||||||||||||
|
Balance at September 30, 2025 (unaudited)
|
|
$
|
|
$
|
|
$
|
( |
)
|
$
|
( |
)
|
|||||||||
| (1) | |
|
For the Nine
Months
Ended
September 30, 2026
|
For the Period
from July 28,
2025 (inception)
through
September 30,
2025
|
|||||||
|
Cash flows from operating activities:
|
||||||||
|
Net loss
|
$
|
( |
)
|
$
|
( |
)
|
||
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
||||||||
|
Interest earned on trust account
|
( |
)
|
||||||
|
Changes in operating assets and liabilities:
|
||||||||
|
Accounts payable
|
( |
)
|
|
|||||
|
Prepaid insurance
|
( |
)
|
|
|||||
|
Non-current prepaid insurance
|
( |
)
|
|
|||||
|
Accrued expenses
|
( |
)
|
|
|||||
|
Due to related party
|
|
|
||||||
|
Advisory fee payable
|
|
|
||||||
|
Net cash used in operating activities
|
( |
)
|
( |
)
|
||||
|
Cash flows from investing activities:
|
||||||||
|
Cash deposited into Trust Account
|
( |
)
|
|
|||||
|
Proceeds from sales of investments
|
|
|
||||||
|
Net cash used in investing activities
|
( |
)
|
|
|||||
|
Cash flows from financing activities:
|
||||||||
|
Promissory note - related party
|
|
|
||||||
|
Deferred offering costs
|
|
( |
)
|
|||||
|
Proceeds from sale of Units, net of underwriting discounts paid
|
|
|
||||||
|
Proceeds from Private Placement Warrants
|
|
|
||||||
|
Proceeds from Public Warrants
|
|
|
||||||
|
Payment of offering costs
|
( |
)
|
|
|||||
|
Repayment of promissory note
|
( |
)
|
|
|||||
|
Net cash provided by financing activities
|
|
|
||||||
|
Net increase in cash and cash equivalents
|
|
|
||||||
|
Cash and cash equivalents, beginning of period
|
|
|
||||||
|
Cash and cash equivalents, end of period
|
$
|
|
$
|
|
||||
|
Supplemental disclosure of non-cash investing and financing activities:
|
||||||||
|
Deferred underwriting fee payable
|
$ |
$ |
||||||
|
Deferred offering costs paid by Sponsor in exchange for issuance of Class B ordinary shares
|
$
|
|
$
|
|
||||
|
Deferred offering costs included in accrued offering costs
|
$
|
|
$
|
|
||||
|
Gross proceeds
|
$
|
|
||
|
Less:
|
||||
|
Proceeds allocated to public warrants
|
( |
)
|
||
|
Issuance costs allocated to Public Shares
|
( |
)
|
||
|
Plus:
|
||||
|
Accretion of carrying value to redemption value
|
|
|||
|
Class A ordinary shares subject to possible redemption
|
$
|
|
|
For the Three Months
Ended September 30, 2026
|
For the Nine Months
Ended September 30, 2026
|
|||||||||||||||
|
Class A
Ordinary
Shares
|
Class B
Ordinary
Shares
|
Class A
Ordinary
Shares
|
Class B
Ordinary
Shares
|
|||||||||||||
|
Basic and diluted net income (loss) per share:
|
||||||||||||||||
|
Numerator:
|
||||||||||||||||
|
Net income (loss)
|
$
|
|
$
|
|
$
|
( |
)
|
$
|
( |
)
|
||||||
|
Denominator:
|
||||||||||||||||
|
Weighted Average Ordinary Shares
|
|
|
|
|
||||||||||||
|
Basic and diluted net income (loss) per ordinary share
|
$
|
|
$
|
|
$
|
( |
)
|
$
|
( |
)
|
||||||
|
For the Period from July 28, 2025
(inception) through September 30,
2025
|
||||||||
|
Class A
Ordinary
Shares
|
Class B
Ordinary
Shares
|
|||||||
|
Basic and diluted net income (loss) per share:
|
||||||||
|
Numerator:
|
||||||||
|
Net income (loss)
|
$
|
|
$
|
( |
)
|
|||
|
Denominator:
|
||||||||
|
Weighted Average Ordinary Shares
|
|
|
||||||
|
Basic and diluted net income (loss) per ordinary share
|
$
|
|
$
|
( |
)
|
|||
|
September 30, 2026
|
December 31, 2025
|
|||||||
|
Cash and Cash Equivalents
|
$
|
|
$
|
|
||||
|
Prepaid insurance - Current
|
|
|
||||||
|
Prepaid insurance - Non-Current
|
|
|
||||||
|
Marketable securities held in Trust Account
|
|
|
||||||
|
Deferred offering costs
|
|
|
||||||
|
Total Assets
|
$
|
|
$
|
|
||||
|
For the Three
Months Ended
September 30,
2026
|
For the Nine
Months
Ended
September 30,
2026
|
For the Period
from July 28,
2025 (inception)
through
September 30,
2025
|
||||||||||
|
General and administrative expenses
|
$
|
|
$
|
|
$
|
|
||||||
|
Loss from operations
|
( |
)
|
( |
)
|
( |
)
|
||||||
|
Other income:
|
||||||||||||
|
Interest income
|
|
|
—
|
|||||||||
|
Net income (loss)
|
$
|
|
$
|
( |
)
|
$
|
( |
)
|
||||
| • | in whole and not in part at a price of $ |
| • | upon a minimum of |
| • | if, and only if, the closing price of the Class A ordinary shares equals or exceeds $ |
| • |
Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;
|
| • |
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for
identical or similar instruments in markets that are not active; and
|
| • |
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one
or more significant inputs or significant value drivers are unobservable. In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair
value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.
|
|
Underlying stock price
|
$
|
|
||
|
Exercise price
|
$
|
|
||
|
Implied Volatility
|
|
%
|
||
|
Weighted-Average remaining term (in years)
|
|
|||
|
Risk-free rate
|
|
%
|
||
|
Implied Market adjustment
|
|
%
|
|
Level
|
September 30, 2026
|
December 31, 2025
|
||||||||||
|
Marketable securities held in Trust Account
|
1
|
$
|
|
$
|
|
|||||||
| ITEM 2. |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
|
| Item 3. |
Quantitative and Qualitative Disclosures About Market Risk
|
| Item 4. |
Controls and Procedures
|
| Item 1. |
Legal Proceedings
|
| Item 1A. |
Risks Factors
|
| Item 2. |
Unregistered Sales of Equity Securities and Use of Proceeds
|
| Item 3. |
Defaults Upon Senior Securities
|
| Item 4. |
Mine Safety Disclosures
|
| Item 5. | |
| Item 6. |
Exhibits
|
|
31.1
|
Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
|
31.2
|
Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
|
32
|
Certification of Principal Executive Officer and the Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of
2002.
|
|
101.INS
|
Inline XBRL Instance Document.
|
|
101.SCH
|
Inline XBRL Taxonomy Extension Schema Document
|
|
101.CAL
|
Inline XBRL Taxonomy Extension Calculation Linkbase Document
|
|
101.DEF
|
Inline XBRL Taxonomy Extension Definition Linkbase Document
|
|
101.LAB
|
Inline XBRL Taxonomy Extension Label Linkbase Document
|
|
101.PRE
|
Inline XBRL Taxonomy Extension Presentation Linkbase Document
|
|
104
|
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
|
|
KRAKacquisition Corp
|
|
|
Date: November 16, 2026
|
/s/ Ravikant Tanuku
|
|
Ravikant Tanuku
|
|
|
Chief Executive Officer
|
|
|
Date: November 16, 2026
|
/s/ Sahil Gupta
|
|
Sahil Gupta
|
|
|
Chief Financial Officer
|